Gilead SciencesGILD

Raymond James set its target for the stock at $164 on Monday. This is slightly higher than the $153 average target from all analysts who follow the company. Since the firm did not change its overall rating on the stock, this is a routine update that reflects a slightly more positive view on the stock's price rather than a change in how they see the business working.

Source: Raymond James

Gilead has signed an agreement with the Pan American Health Organization to provide lenacapavir, a long-acting drug used for HIV prevention, across Latin America and the Caribbean. The partnership uses a regional fund to help countries in these areas buy the drug more easily and coordinate their health efforts.

This is a meaningful step for lenacapavir, which only needs to be injected twice a year rather than taken as a daily pill. While the financial impact of this specific regional deal may be small compared to total sales, it helps establish the drug as a global standard for prevention. For long-term owners, this supports the view that Gilead can maintain its lead in the HIV market by moving patients toward newer, more convenient treatments.

Source: Business Wire

HSBC raised its price target for Gilead from $155 to $175 while keeping a buy rating on the stock. This new target is slightly higher than the $150 average across all Wall Street firms. Because the rating did not change, this is a routine update that reflects the stock's recent climb rather than a shift in how analysts view the business. The move suggests the firm remains confident in Gilead's ability to grow its HIV and cancer drug sales.

Source: HSBC

Gilead opened a new research center at its headquarters in Foster City. The facility is designed to help the company develop its next round of treatments. While a new building is a routine part of a large drugmaker's operations, it supports the company's long-term goal of expanding beyond its core HIV business into new areas like cancer and autoimmune diseases.

Source: Business Wire

The U.S. Food and Drug Administration (FDA) approved a new once-daily oral treatment for adults whose HIV levels are already very low. This pill is designed as a simpler option for patients who are stable on their current treatments but want to switch to a single daily dose.

This approval helps protect the company's lead in the HIV market. While Gilead already dominates this space with its Biktarvy drug, adding new options for stable patients makes it harder for rivals to win them over. It ensures the HIV business continues to act as a reliable source of cash to fund the company's newer work in cancer treatments.

Source: Reuters

Metrics we are tracking